AbCellera (NASDAQ:ABCL) announced today that it has expanded its existing multi-target collaboration with Regeneron (NASDAQ:REGN) to discover therapeutic antibodies for up to eight targets selected by Regeneron,
Viceroy's Numerous Defamatory, False and Misleading Claims Have Caused Serious Harm to MPT and its Investors
Shareholder Letter Corrects Record Regarding Short-Selling Firm's Baseless Allegations